Cytokinetics (NASDAQ: CYTK) reported Q4 EPS of ($0.48), $0.04 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $9.38 million versus the consensus estimate of $3.94 million.

“We had a productive fourth quarter 2018 highlighted by the expansion of our clinical pipeline of muscle-directed investigational medicines and the advancement of our wholly-owned cardiac myosin inhibitor which we are developing for the potential treatment of patients with hypertrophic cardiomyopathies,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “Our progress is continuing with the achievement of key milestones under our partnered programs. Under our collaboration with Amgen, we recently opened METEORIC-HF to enrollment and expect GALACTIC-HF to complete enrollment in the next few months. In that same timeframe, we are also looking forward to results from FORTITUDE-ALS under our collaboration with Astellas. We believe that our pioneering leadership in muscle biology, alongside our partnerships and current financials, position us well for upcoming company milestones.”

GUIDANCE:

Cytokinetics sees FY2020 revenue of $28-32 million, versus the consensus of $28.87 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.